{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:17:55Z","timestamp":1788315475102,"version":"build-2803163510"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T00:00:00Z","timestamp":1720742400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["EnVision CF: Emerging Leaders in CF Endocrinology"],"award-info":[{"award-number":["EnVision CF: Emerging Leaders in CF Endocrinology"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["Harry Shwachman Clinical Investigator Award"],"award-info":[{"award-number":["Harry Shwachman Clinical Investigator Award"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","award":["R01DK119699"],"award-info":[{"award-number":["R01DK119699"]}],"id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2024,10]]},"DOI":"10.1007\/s00125-024-06223-3","type":"journal-article","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T05:02:16Z","timestamp":1720760536000},"page":"2143-2153","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Advances in diabetes technology to improve the lives of people with cystic fibrosis"],"prefix":"10.1007","volume":"67","author":[{"given":"Kevin J.","family":"Scully","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brynn E.","family":"Marks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7655-8954","authenticated-orcid":false,"given":"Melissa S.","family":"Putman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,12]]},"reference":[{"key":"6223_CR1","unstructured":"Cystic Fibrosis Foundation Patient Registry (2022) Annual data report. Available from: www.cff.org\/medical-professionals\/patient-registry. Accessed: 2 April 2024"},{"issue":"12","key":"6223_CR2","doi-asserted-by":"publisher","first-page":"e81545","DOI":"10.1371\/journal.pone.0081545","volume":"8","author":"N Scheuing","year":"2013","unstructured":"Scheuing N, Holl RW, Dockter G et al (2013) Diabetes in cystic fibrosis: multicenter screening results based on current guidelines. PLoS One 8(12):e81545. https:\/\/doi.org\/10.1371\/journal.pone.0081545","journal-title":"PLoS One"},{"issue":"3","key":"6223_CR3","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jcte.2014.07.003","volume":"1","author":"K Millington","year":"2014","unstructured":"Millington K, Miller V, Rubenstein RC, Kelly A (2014) Patient and parent perceptions of the diagnosis and management of cystic fibrosis-related diabetes. J Clin Transl Endocrinol 1(3):100\u2013107. https:\/\/doi.org\/10.1016\/j.jcte.2014.07.003","journal-title":"J Clin Transl Endocrinol"},{"issue":"5","key":"6223_CR4","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1016\/j.jcf.2019.03.007","volume":"18","author":"E Kwong","year":"2019","unstructured":"Kwong E, Desai S, Chong L et al (2019) The impact of cystic fibrosis-related diabetes on health-related quality of life. J Cyst Fibros 18(5):734\u2013736. https:\/\/doi.org\/10.1016\/j.jcf.2019.03.007","journal-title":"J Cyst Fibros"},{"issue":"1","key":"6223_CR5","doi-asserted-by":"publisher","first-page":"R35","DOI":"10.1530\/JOE-18-0468","volume":"241","author":"AW Norris","year":"2019","unstructured":"Norris AW, Ode KL, Merjaneh L et al (2019) Survival in a bad neighborhood: pancreatic islets in cystic fibrosis. J Endocrinol 241(1):R35\u2013R50. https:\/\/doi.org\/10.1530\/JOE-18-0468","journal-title":"J Endocrinol"},{"issue":"6","key":"6223_CR6","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.jcf.2008.05.008","volume":"7","author":"JM van den Berg","year":"2008","unstructured":"van den Berg JM, Morton AM, Kok SW, Pijl H, Conway SP, Heijerman HG (2008) Microvascular complications in patients with cystic fibrosis-related diabetes (CFRD). J Cyst Fibros 7(6):515\u2013519. https:\/\/doi.org\/10.1016\/j.jcf.2008.05.008","journal-title":"J Cyst Fibros"},{"key":"6223_CR7","doi-asserted-by":"publisher","first-page":"100308","DOI":"10.1016\/j.jcte.2022.100308","volume":"30","author":"Z Sandouk","year":"2022","unstructured":"Sandouk Z, Nachawi N, Simon R et al (2022) Coronary artery disease in patients with cystic fibrosis - a case series and review of the literature. J Clin Transl Endocrinol 30:100308. https:\/\/doi.org\/10.1016\/j.jcte.2022.100308","journal-title":"J Clin Transl Endocrinol"},{"issue":"7","key":"6223_CR8","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1002\/dmrr.2429","volume":"29","author":"K Konrad","year":"2013","unstructured":"Konrad K, Scheuing N, Badenhoop K et al (2013) Cystic fibrosis-related diabetes compared with type 1 and type 2 diabetes in adults. Diabetes Metab Res Rev 29(7):568\u2013575. https:\/\/doi.org\/10.1002\/dmrr.2429","journal-title":"Diabetes Metab Res Rev"},{"issue":"9","key":"6223_CR9","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.2337\/dc09-0586","volume":"32","author":"A Moran","year":"2009","unstructured":"Moran A, Dunitz J, Nathan B, Saeed A, Holme B, Thomas W (2009) Cystic fibrosis-related diabetes: current trends in prevalence, incidence, and mortality. Diabetes Care 32(9):1626\u20131631. https:\/\/doi.org\/10.2337\/dc09-0586","journal-title":"Diabetes Care"},{"issue":"2","key":"6223_CR10","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1164\/rccm.201403-0576OC","volume":"191","author":"C Lewis","year":"2015","unstructured":"Lewis C, Blackman SM, Nelson A et al (2015) Diabetes-related mortality in adults with cystic fibrosis. Role of genotype and sex. Am J Respir Crit Care Med 191(2):194\u2013200. https:\/\/doi.org\/10.1164\/rccm.201403-0576OC","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"6223_CR11","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.2337\/dc10-2289","volume":"34","author":"AI Adler","year":"2011","unstructured":"Adler AI, Shine B, Haworth C, Leelarathna L, Bilton D (2011) Hyperglycemia and death in cystic fibrosis-related diabetes. Diabetes Care 34(7):1577\u20131578. https:\/\/doi.org\/10.2337\/dc10-2289","journal-title":"Diabetes Care"},{"issue":"2","key":"6223_CR12","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2337\/dc09-1215","volume":"33","author":"P Chamnan","year":"2010","unstructured":"Chamnan P, Shine BS, Haworth CS, Bilton D, Adler AI (2010) Diabetes as a determinant of mortality in cystic fibrosis. Diabetes Care 33(2):311\u2013316. https:\/\/doi.org\/10.2337\/dc09-1215","journal-title":"Diabetes Care"},{"issue":"5","key":"6223_CR13","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/j.jpeds.2004.12.039","volume":"146","author":"BC Marshall","year":"2005","unstructured":"Marshall BC, Butler SM, Stoddard M, Moran AM, Liou TG, Morgan WJ (2005) Epidemiology of cystic fibrosis-related diabetes. J Pediatr 146(5):681\u2013687. https:\/\/doi.org\/10.1016\/j.jpeds.2004.12.039","journal-title":"J Pediatr"},{"issue":"2","key":"6223_CR14","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.jcf.2006.03.009","volume":"6","author":"AL Brennan","year":"2007","unstructured":"Brennan AL, Gyi KM, Wood DM et al (2007) Airway glucose concentrations and effect on growth of respiratory pathogens in cystic fibrosis. J Cyst Fibros 6(2):101\u2013109. https:\/\/doi.org\/10.1016\/j.jcf.2006.03.009","journal-title":"J Cyst Fibros"},{"issue":"1","key":"6223_CR15","doi-asserted-by":"publisher","first-page":"L43","DOI":"10.1152\/ajplung.00224.2013","volume":"306","author":"WR Hunt","year":"2014","unstructured":"Hunt WR, Zughaier SM, Guentert DE et al (2014) Hyperglycemia impedes lung bacterial clearance in a murine model of cystic fibrosis-related diabetes. Am J Physiol Lung Cell Mol Physiol 306(1):L43\u2013L49. https:\/\/doi.org\/10.1152\/ajplung.00224.2013","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"key":"6223_CR16","doi-asserted-by":"publisher","first-page":"37955","DOI":"10.1038\/srep37955","volume":"6","author":"JP Garnett","year":"2016","unstructured":"Garnett JP, Kalsi KK, Sobotta M et al (2016) Hyperglycaemia and Pseudomonas aeruginosa acidify cystic fibrosis airway surface liquid by elevating epithelial monocarboxylate transporter 2 dependent lactate-H+ secretion. Sci Rep 6:37955. https:\/\/doi.org\/10.1038\/srep37955","journal-title":"Sci Rep"},{"issue":"1","key":"6223_CR17","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jcf.2015.04.002","volume":"15","author":"C Bilodeau","year":"2016","unstructured":"Bilodeau C, Bardou O, Maille E, Berthiaume Y, Brochiero E (2016) Deleterious impact of hyperglycemia on cystic fibrosis airway ion transport and epithelial repair. J Cyst Fibros 15(1):43\u201351. https:\/\/doi.org\/10.1016\/j.jcf.2015.04.002","journal-title":"J Cyst Fibros"},{"issue":"6","key":"6223_CR18","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.jcf.2018.03.008","volume":"17","author":"CL Chan","year":"2018","unstructured":"Chan CL, Vigers T, Pyle L, Zeitler PS, Sagel SD, Nadeau KJ (2018) Continuous glucose monitoring abnormalities in cystic fibrosis youth correlate with pulmonary function decline. J Cyst Fibros 17(6):783\u2013790. https:\/\/doi.org\/10.1016\/j.jcf.2018.03.008","journal-title":"J Cyst Fibros"},{"issue":"6","key":"6223_CR19","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1016\/j.jcf.2019.03.010","volume":"18","author":"BJ Prentice","year":"2019","unstructured":"Prentice BJ, Ooi CY, Strachan RE et al (2019) Early glucose abnormalities are associated with pulmonary inflammation in young children with cystic fibrosis. J Cyst Fibros 18(6):869\u2013873. https:\/\/doi.org\/10.1016\/j.jcf.2019.03.010","journal-title":"J Cyst Fibros"},{"issue":"2","key":"6223_CR20","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1016\/j.jcf.2019.05.005","volume":"19","author":"BJ Prentice","year":"2020","unstructured":"Prentice BJ, Chelliah A, Ooi CY et al (2020) Peak OGTT glucose is associated with lower lung function in young children with cystic fibrosis. J Cyst Fibros 19(2):305\u2013309. https:\/\/doi.org\/10.1016\/j.jcf.2019.05.005","journal-title":"J Cyst Fibros"},{"issue":"4","key":"6223_CR21","doi-asserted-by":"publisher","first-page":"e1444","DOI":"10.1210\/clinem\/dgab857","volume":"107","author":"KJ Scully","year":"2022","unstructured":"Scully KJ, Sherwood JS, Martin K et al (2022) Continuous glucose monitoring and HbA1c in cystic fibrosis: clinical correlations and implications for CFRD diagnosis. J Clin Endocrinol Metab 107(4):e1444\u2013e1454. https:\/\/doi.org\/10.1210\/clinem\/dgab857","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"6223_CR22","doi-asserted-by":"publisher","first-page":"e00208","DOI":"10.1002\/edm2.208","volume":"4","author":"L Merjaneh","year":"2021","unstructured":"Merjaneh L, Toprak D, McNamara S, Nay L, Sullivan E, Rosenfeld M (2021) Acute hyperglycaemia in cystic fibrosis pulmonary exacerbations. Endocrinol Diabetes Metab 4(2):e00208. https:\/\/doi.org\/10.1002\/edm2.208","journal-title":"Endocrinol Diabetes Metab"},{"issue":"5","key":"6223_CR23","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.jcf.2021.03.004","volume":"20","author":"M Pallin","year":"2021","unstructured":"Pallin M, Kumar S, Daley C et al (2021) Continuous glucose monitoring indices predict poor FEV1 recovery following cystic fibrosis pulmonary exacerbations. J Cyst Fibros 20(5):785\u2013791. https:\/\/doi.org\/10.1016\/j.jcf.2021.03.004","journal-title":"J Cyst Fibros"},{"issue":"6","key":"6223_CR24","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1136\/archdischild-2017-314250","volume":"103","author":"M Zorron Mei Hsia Pu","year":"2018","unstructured":"Zorron Mei Hsia Pu M, Goncalves AC, Minnicucci WJ, Morcillo AM, Ribeiro JD, Ribeiro AF (2018) Continuous glucose monitoring to evaluate glycaemic abnormalities in cystic fibrosis. Arch Dis Child 103(6):592\u2013596. https:\/\/doi.org\/10.1136\/archdischild-2017-314250","journal-title":"Arch Dis Child"},{"issue":"4","key":"6223_CR25","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jcf.2013.11.005","volume":"13","author":"A Leclercq","year":"2014","unstructured":"Leclercq A, Gauthier B, Rosner V et al (2014) Early assessment of glucose abnormalities during continuous glucose monitoring associated with lung function impairment in cystic fibrosis patients. J Cyst Fibros 13(4):478\u2013484. https:\/\/doi.org\/10.1016\/j.jcf.2013.11.005","journal-title":"J Cyst Fibros"},{"issue":"7","key":"6223_CR26","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1055\/s-2008-1062723","volume":"40","author":"F Moreau","year":"2008","unstructured":"Moreau F, Weiller MA, Rosner V et al (2008) Continuous glucose monitoring in cystic fibrosis patients according to the glucose tolerance. Horm Metab Res 40(7):502\u2013506. https:\/\/doi.org\/10.1055\/s-2008-1062723","journal-title":"Horm Metab Res"},{"issue":"4","key":"6223_CR27","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1530\/EJE-09-1020","volume":"162","author":"R Schiaffini","year":"2010","unstructured":"Schiaffini R, Brufani C, Russo B et al (2010) Abnormal glucose tolerance in children with cystic fibrosis: the predictive role of continuous glucose monitoring system. Eur J Endocrinol 162(4):705\u2013710. https:\/\/doi.org\/10.1530\/EJE-09-1020","journal-title":"Eur J Endocrinol"},{"key":"6223_CR28","doi-asserted-by":"publisher","first-page":"1527932","DOI":"10.1155\/2016\/1527932","volume":"2016","author":"JL Taylor-Cousar","year":"2016","unstructured":"Taylor-Cousar JL, Janssen JS, Wilson A et al (2016) Glucose >200 mg\/dl during continuous glucose monitoring identifies adult patients at risk for development of cystic fibrosis related diabetes. J Diabetes Res 2016:1527932. https:\/\/doi.org\/10.1155\/2016\/1527932","journal-title":"J Diabetes Res"},{"issue":"2","key":"6223_CR29","doi-asserted-by":"publisher","first-page":"e20210307","DOI":"10.36416\/1806-3756\/e20210307","volume":"48","author":"M Zorron","year":"2022","unstructured":"Zorron M, Marson FAL, Morcillo AM et al (2022) Can continuous glucose monitoring predict cystic fibrosis-related diabetes and worse clinical outcome? J Bras Pneumol 48(2):e20210307. https:\/\/doi.org\/10.36416\/1806-3756\/e20210307","journal-title":"J Bras Pneumol"},{"issue":"5","key":"6223_CR30","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jcf.2020.02.009","volume":"19","author":"BJ Prentice","year":"2020","unstructured":"Prentice BJ, Ooi CY, Verge CF, Hameed S, Widger J (2020) Glucose abnormalities detected by continuous glucose monitoring are common in young children with cystic fibrosis. J Cyst Fibros 19(5):700\u2013703. https:\/\/doi.org\/10.1016\/j.jcf.2020.02.009","journal-title":"J Cyst Fibros"},{"issue":"2","key":"6223_CR31","doi-asserted-by":"publisher","first-page":"221","DOI":"10.2337\/dc09-1492","volume":"33","author":"S Hameed","year":"2010","unstructured":"Hameed S, Morton JR, Jaffe A et al (2010) Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care 33(2):221\u2013226. https:\/\/doi.org\/10.2337\/dc09-1492","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"6223_CR32","doi-asserted-by":"publisher","first-page":"S19","DOI":"10.1016\/j.jcf.2019.08.004","volume":"18","author":"A Moheet","year":"2019","unstructured":"Moheet A, Chan CL, Granados A, Ode KL, Moran A, Battezzati A (2019) Hypoglycemia in cystic fibrosis: prevalence, impact and treatment. J Cyst Fibros 18(Suppl 2):S19\u2013S24. https:\/\/doi.org\/10.1016\/j.jcf.2019.08.004","journal-title":"J Cyst Fibros"},{"issue":"4","key":"6223_CR33","doi-asserted-by":"publisher","first-page":"e1793","DOI":"10.1210\/clinem\/dgaa932","volume":"106","author":"C Piona","year":"2021","unstructured":"Piona C, Volpi S, Zusi C et al (2021) Glucose tolerance stages in cystic fibrosis are identified by a unique pattern of defects of beta-cell function. J Clin Endocrinol Metab 106(4):e1793\u2013e1802. https:\/\/doi.org\/10.1210\/clinem\/dgaa932","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"6223_CR34","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jcf.2021.09.001","volume":"21","author":"KJ Scully","year":"2022","unstructured":"Scully KJ, Marchetti P, Sawicki GS et al (2022) The effect of elexacaftor\/tezacaftor\/ivacaftor (ETI) on glycemia in adults with cystic fibrosis. J Cyst Fibros 21(2):258\u2013263. https:\/\/doi.org\/10.1016\/j.jcf.2021.09.001","journal-title":"J Cyst Fibros"},{"issue":"1","key":"6223_CR35","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.jcf.2023.11.005","volume":"23","author":"BU Nielsen","year":"2023","unstructured":"Nielsen BU, Olsen MF, MabuzaMathiesen IH et al (2023) Decline in HbA1c during the first year of elexacaftor\/tezacaftor\/ivacaftor treatment in the Danish cystic fibrosis cohort. Short title: decline in HbA1c after elexacaftor\/tezacaftor\/ivacaftor treatment. J Cyst Fibros 23(1):103\u2013108. https:\/\/doi.org\/10.1016\/j.jcf.2023.11.005","journal-title":"J Cyst Fibros"},{"issue":"5","key":"6223_CR36","doi-asserted-by":"publisher","first-page":"101466","DOI":"10.1016\/j.diabet.2023.101466","volume":"49","author":"V Grancini","year":"2023","unstructured":"Grancini V, Gramegna A, Zazzeron L et al (2023) Effects of elexacaftor \/ tezacaftor \/ ivacaftor triple combination therapy on glycaemic control and body composition in patients with cystic fibrosis-related diabetes. Diabetes Metab 49(5):101466. https:\/\/doi.org\/10.1016\/j.diabet.2023.101466","journal-title":"Diabetes Metab"},{"issue":"4","key":"6223_CR37","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/j.jcf.2023.01.004","volume":"22","author":"C Steinack","year":"2023","unstructured":"Steinack C, Ernst M, Beuschlein F et al (2023) Improved glucose tolerance after initiation of elexacaftor \/ tezacaftor \/ ivacaftor in adults with cystic fibrosis. J Cyst Fibros 22(4):722\u2013729. https:\/\/doi.org\/10.1016\/j.jcf.2023.01.004","journal-title":"J Cyst Fibros"},{"key":"6223_CR38","doi-asserted-by":"publisher","first-page":"100311","DOI":"10.1016\/j.jcte.2022.100311","volume":"30","author":"CL Chan","year":"2022","unstructured":"Chan CL, Granados A, Moheet A et al (2022) Glycemia and beta-cell function before and after elexacaftor\/tezacaftor\/ivacaftor in youth and adults with cystic fibrosis. J Clin Transl Endocrinol 30:100311. https:\/\/doi.org\/10.1016\/j.jcte.2022.100311","journal-title":"J Clin Transl Endocrinol"},{"issue":"1","key":"6223_CR39","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1210\/clinem\/dgad443","volume":"109","author":"AJ Flatt","year":"2023","unstructured":"Flatt AJ, Sheikh S, Peleckis AJ et al (2023) Preservation of \u03b2-cell function in pancreatic insufficient cystic fibrosis with highly effective cftr modulator therapy. J Clin Endocrinol Metab 109(1):151\u2013160. https:\/\/doi.org\/10.1210\/clinem\/dgad443","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"6223_CR40","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.2337\/dc10-1768","volume":"33","author":"A Moran","year":"2010","unstructured":"Moran A, Brunzell C, Cohen RC et al (2010) Clinical care guidelines for cystic fibrosis-related diabetes: a position statement of the American Diabetes Association and a clinical practice guideline of the Cystic Fibrosis Foundation, endorsed by the Pediatric Endocrine Society. Diabetes Care 33(12):2697\u20132708. https:\/\/doi.org\/10.2337\/dc10-1768","journal-title":"Diabetes Care"},{"issue":"8","key":"6223_CR41","doi-asserted-by":"publisher","first-page":"1212","DOI":"10.1111\/pedi.13453","volume":"23","author":"KL Ode","year":"2022","unstructured":"Ode KL, Ballman M, Battezzati A et al (2022) ISPAD clinical practice consensus guidelines 2022: management of cystic fibrosis-related diabetes in children and adolescents. Pediatr Diabetes 23(8):1212\u20131228. https:\/\/doi.org\/10.1111\/pedi.13453","journal-title":"Pediatr Diabetes"},{"issue":"3 Pt 1","key":"6223_CR42","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1164\/ajrccm.162.3.9904075","volume":"162","author":"CE Milla","year":"2000","unstructured":"Milla CE, Warwick WJ, Moran A (2000) Trends in pulmonary function in patients with cystic fibrosis correlate with the degree of glucose intolerance at baseline. Am J Respir Crit Care Med 162(3 Pt 1):891\u2013895. https:\/\/doi.org\/10.1164\/ajrccm.162.3.9904075","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"6223_CR43","doi-asserted-by":"publisher","first-page":"e112578","DOI":"10.1371\/journal.pone.0112578","volume":"9","author":"N Scheuing","year":"2014","unstructured":"Scheuing N, Holl RW, Dockter G et al (2014) High variability in oral glucose tolerance among 1,128 patients with cystic fibrosis: a multicenter screening study. PLoS One 9(11):e112578. https:\/\/doi.org\/10.1371\/journal.pone.0112578","journal-title":"PLoS One"},{"issue":"7","key":"6223_CR44","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.2337\/dc17-2419","volume":"41","author":"CL Chan","year":"2018","unstructured":"Chan CL, Hope E, Thurston J et al (2018) Hemoglobin A1c accurately predicts continuous glucose monitoring-derived average glucose in youth and young adults with cystic fibrosis. Diabetes Care 41(7):1406\u20131413. https:\/\/doi.org\/10.2337\/dc17-2419","journal-title":"Diabetes Care"},{"key":"6223_CR45","doi-asserted-by":"publisher","first-page":"1293709","DOI":"10.3389\/fendo.2024.1293709","volume":"15","author":"KJ Scully","year":"2024","unstructured":"Scully KJ, Brenner L, Martin K et al (2024) Continuous glucose monitoring and advanced glycation endproducts for prediction of clinical outcomes and development of cystic fibrosis-related diabetes in adults with CF. Front Endocrinol 15:1293709. https:\/\/doi.org\/10.3389\/fendo.2024.1293709","journal-title":"Front Endocrinol"},{"key":"6223_CR46","doi-asserted-by":"publisher","first-page":"100323","DOI":"10.1016\/j.jcte.2023.100323","volume":"33","author":"K Kutney","year":"2023","unstructured":"Kutney K, Kaminski BA, Casey T, O\u2019Riordan M, Gubitosi-Klug R (2023) Reproducibility of in-home CFRD screening using continuous glucose monitoring and mixed meal tolerance test. J Clin Transl Endocrinol 33:100323. https:\/\/doi.org\/10.1016\/j.jcte.2023.100323","journal-title":"J Clin Transl Endocrinol"},{"key":"6223_CR47","doi-asserted-by":"publisher","first-page":"100305","DOI":"10.1016\/j.jcte.2022.100305","volume":"30","author":"S Kumar","year":"2022","unstructured":"Kumar S, Pallin M, Soldatos G, Teede H (2022) Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic fibrosis: a systematic review. J Clin Transl Endocrinol 30:100305. https:\/\/doi.org\/10.1016\/j.jcte.2022.100305","journal-title":"J Clin Transl Endocrinol"},{"issue":"2","key":"6223_CR48","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jcf.2024.01.005","volume":"23","author":"PR Burgel","year":"2024","unstructured":"Burgel PR, Southern KW, Addy C et al (2024) Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues. J Cyst Fibros 23(2):187\u2013202. https:\/\/doi.org\/10.1016\/j.jcf.2024.01.005","journal-title":"J Cyst Fibros"},{"key":"6223_CR49","doi-asserted-by":"publisher","first-page":"100298","DOI":"10.1016\/j.jcte.2022.100298","volume":"28","author":"L Weiss","year":"2022","unstructured":"Weiss L, Ronsin O, Reynaud Q et al (2022) Clinical practice versus guidelines for the screening of cystic fibrosis-related diabetes: a French survey from the 47 centers. J Clin Transl Endocrinol 28:100298. https:\/\/doi.org\/10.1016\/j.jcte.2022.100298","journal-title":"J Clin Transl Endocrinol"},{"key":"6223_CR50","doi-asserted-by":"publisher","first-page":"1183288","DOI":"10.3389\/fendo.2023.1183288","volume":"14","author":"R Hicks","year":"2023","unstructured":"Hicks R, Ode KL, Vigers T, Chan CL (2023) A provider survey of cystic fibrosis related diabetes screening and management practices at North American CF centers. Front Endocrinol 14:1183288. https:\/\/doi.org\/10.3389\/fendo.2023.1183288","journal-title":"Front Endocrinol"},{"issue":"10","key":"6223_CR51","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.2337\/dc09-0585","volume":"32","author":"A Moran","year":"2009","unstructured":"Moran A, Pekow P, Grover P et al (2009) Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care 32(10):1783\u20131788. https:\/\/doi.org\/10.2337\/dc09-0585","journal-title":"Diabetes Care"},{"issue":"2","key":"6223_CR52","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1159\/000110206","volume":"76","author":"K Mohan","year":"2008","unstructured":"Mohan K, Israel KL, Miller H, Grainger R, Ledson MJ, Walshaw MJ (2008) Long-term effect of insulin treatment in cystic fibrosis-related diabetes. Respiration 76(2):181\u2013186. https:\/\/doi.org\/10.1159\/000110206","journal-title":"Respiration"},{"key":"6223_CR53","doi-asserted-by":"publisher","first-page":"100267","DOI":"10.1016\/j.jcte.2021.100267","volume":"26","author":"R Hicks","year":"2021","unstructured":"Hicks R, Marks BE, Oxman R, Moheet A (2021) Spontaneous and iatrogenic hypoglycemia in cystic fibrosis. J Clin Transl Endocrinol 26:100267. https:\/\/doi.org\/10.1016\/j.jcte.2021.100267","journal-title":"J Clin Transl Endocrinol"},{"issue":"11","key":"6223_CR54","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1089\/dia.2021.0201","volume":"23","author":"BE Marks","year":"2021","unstructured":"Marks BE, Kilberg MJ, Aliaj E et al (2021) Perceptions of diabetes technology use in cystic fibrosis-related diabetes management. Diabetes Technol Ther 23(11):753\u2013759. https:\/\/doi.org\/10.1089\/dia.2021.0201","journal-title":"Diabetes Technol Ther"},{"issue":"6","key":"6223_CR55","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.jcf.2018.05.005","volume":"17","author":"F Frost","year":"2018","unstructured":"Frost F, Dyce P, Nazareth D, Malone V, Walshaw MJ (2018) Continuous glucose monitoring guided insulin therapy is associated with improved clinical outcomes in cystic fibrosis-related diabetes. J Cyst Fibros 17(6):798\u2013803. https:\/\/doi.org\/10.1016\/j.jcf.2018.05.005","journal-title":"J Cyst Fibros"},{"issue":"1","key":"6223_CR56","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.jcf.2022.07.013","volume":"22","author":"S Kumar","year":"2023","unstructured":"Kumar S, Soldatos G, Ranasinha S, Teede H, Pallin M (2023) Continuous glucose monitoring versus self-monitoring of blood glucose in the management of cystic fibrosis related diabetes: a systematic review and meta-analysis. J Cyst Fibros 22(1):39\u201349. https:\/\/doi.org\/10.1016\/j.jcf.2022.07.013","journal-title":"J Cyst Fibros"},{"issue":"3","key":"6223_CR57","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1111\/cen.13290","volume":"86","author":"K Benkhadra","year":"2017","unstructured":"Benkhadra K, Alahdab F, Tamhane S et al (2017) Real-time continuous glucose monitoring in type 1 diabetes: a systematic review and individual patient data meta-analysis. Clin Endocrinol 86(3):354\u2013360. https:\/\/doi.org\/10.1111\/cen.13290","journal-title":"Clin Endocrinol"},{"issue":"3","key":"6223_CR58","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jcf.2008.12.001","volume":"8","author":"DS Hardin","year":"2009","unstructured":"Hardin DS, Rice J, Rice M, Rosenblatt R (2009) Use of the insulin pump in treat cystic fibrosis related diabetes. J Cyst Fibros 8(3):174\u2013178. https:\/\/doi.org\/10.1016\/j.jcf.2008.12.001","journal-title":"J Cyst Fibros"},{"issue":"13","key":"6223_CR59","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1001\/jama.2016.11708","volume":"316","author":"RM Bergenstal","year":"2016","unstructured":"Bergenstal RM, Garg S, Weinzimer SA et al (2016) Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA 316(13):1407\u20131408. https:\/\/doi.org\/10.1001\/jama.2016.11708","journal-title":"JAMA"},{"issue":"10270","key":"6223_CR60","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/S0140-6736(20)32514-9","volume":"397","author":"RM Bergenstal","year":"2021","unstructured":"Bergenstal RM, Nimri R, Beck RW et al (2021) A comparison of two hybrid closed-loop systems in adolescents and young adults with type 1 diabetes (FLAIR): a multicentre, randomised, crossover trial. Lancet 397(10270):208\u2013219. https:\/\/doi.org\/10.1016\/S0140-6736(20)32514-9","journal-title":"Lancet"},{"issue":"7","key":"6223_CR61","doi-asserted-by":"publisher","first-page":"1630","DOI":"10.2337\/dc21-0172","volume":"44","author":"SA Brown","year":"2021","unstructured":"Brown SA, Forlenza GP, Bode BW et al (2021) Multicenter trial of a tubeless, on-body automated insulin delivery system with customizable glycemic targets in pediatric and adult participants with type 1 diabetes. Diabetes Care 44(7):1630\u20131640. https:\/\/doi.org\/10.2337\/dc21-0172","journal-title":"Diabetes Care"},{"issue":"18","key":"6223_CR62","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1056\/NEJMoa1907863","volume":"381","author":"SA Brown","year":"2019","unstructured":"Brown SA, Kovatchev BP, Raghinaru D et al (2019) Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med 381(18):1707\u20131717. https:\/\/doi.org\/10.1056\/NEJMoa1907863","journal-title":"N Engl J Med"},{"issue":"6","key":"6223_CR63","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1089\/dia.2021.0354","volume":"24","author":"KJ Scully","year":"2022","unstructured":"Scully KJ, Palani G, Zheng H, Moheet A, Putman MS (2022) The effect of control IQ hybrid closed loop technology on glycemic control in adolescents and adults with cystic fibrosis related diabetes. Diabetes Technol Ther 24(6):446\u2013452. https:\/\/doi.org\/10.1089\/dia.2021.0354","journal-title":"Diabetes Technol Ther"},{"key":"6223_CR64","doi-asserted-by":"publisher","first-page":"1228153","DOI":"10.3389\/fendo.2023.1228153","volume":"14","author":"V Grancini","year":"2023","unstructured":"Grancini V, Alicandro G, Porcaro LL et al (2023) Effects of insulin therapy optimization with sensor augmented pumps on glycemic control and body composition in people with cystic fibrosis-related diabetes. Front Endocrinol 14:1228153. https:\/\/doi.org\/10.3389\/fendo.2023.1228153","journal-title":"Front Endocrinol"},{"issue":"10","key":"6223_CR65","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1089\/dia.2022.0200","volume":"24","author":"D Kruger","year":"2022","unstructured":"Kruger D, Kass A, Lonier J et al (2022) A multicenter randomized trial evaluating the insulin-only configuration of the bionic pancreas in adults with type 1 diabetes. Diabetes Technol Ther 24(10):697\u2013711. https:\/\/doi.org\/10.1089\/dia.2022.0200","journal-title":"Diabetes Technol Ther"},{"issue":"10","key":"6223_CR66","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1089\/dia.2022.0341","volume":"24","author":"J Lynch","year":"2022","unstructured":"Lynch J, Kanapka LG, Russell SJ et al (2022) The insulin-only bionic pancreas pivotal trial extension study: a multi-center single-arm evaluation of the insulin-only configuration of the bionic pancreas in adults and youth with type 1 diabetes. Diabetes Technol Ther 24(10):726\u2013736. https:\/\/doi.org\/10.1089\/dia.2022.0341","journal-title":"Diabetes Technol Ther"},{"issue":"10","key":"6223_CR67","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1089\/dia.2022.0201.pub","volume":"24","author":"LH Messer","year":"2022","unstructured":"Messer LH, Buckingham BA, Cogen F et al (2022) Positive impact of the bionic pancreas on diabetes control in youth 6\u201317 years old with type 1 diabetes: a multicenter randomized trial. Diabetes Technol Ther 24(10):712\u2013725. https:\/\/doi.org\/10.1089\/dia.2022.0201.pub","journal-title":"Diabetes Technol Ther"},{"issue":"13","key":"6223_CR68","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1056\/NEJMoa2205225","volume":"387","author":"Bionic Pancreas Research Group","year":"2022","unstructured":"Bionic Pancreas Research Group (2022) Multicenter, randomized trial of a bionic pancreas in type 1 diabetes. N Engl J Med 387(13):1161\u20131172. https:\/\/doi.org\/10.1056\/NEJMoa2205225","journal-title":"N Engl J Med"},{"issue":"1","key":"6223_CR69","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.jcf.2019.08.002","volume":"19","author":"JS Sherwood","year":"2020","unstructured":"Sherwood JS, Jafri RZ, Balliro CA et al (2020) Automated glycemic control with the bionic pancreas in cystic fibrosis-related diabetes: a pilot study. J Cyst Fibros 19(1):159\u2013161. https:\/\/doi.org\/10.1016\/j.jcf.2019.08.002","journal-title":"J Cyst Fibros"},{"issue":"1","key":"6223_CR70","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2337\/dc23-1411","volume":"47","author":"JS Sherwood","year":"2024","unstructured":"Sherwood JS, Castellanos LE, O\u2019Connor MY et al (2024) Randomized trial of the insulin-only ilet bionic pancreas for the treatment of cystic fibrosis-related diabetes. Diabetes Care 47(1):101\u2013108. https:\/\/doi.org\/10.2337\/dc23-1411","journal-title":"Diabetes Care"},{"issue":"Suppl 2","key":"6223_CR71","doi-asserted-by":"publisher","first-page":"S10","DOI":"10.1016\/j.jcf.2019.08.003","volume":"18","author":"KL Ode","year":"2019","unstructured":"Ode KL, Chan CL, Granados A, Moheet A, Moran A, Brennan AL (2019) Cystic fibrosis related diabetes: medical management. J Cyst Fibros 18(Suppl 2):S10\u2013S18. https:\/\/doi.org\/10.1016\/j.jcf.2019.08.003","journal-title":"J Cyst Fibros"},{"issue":"10","key":"6223_CR72","doi-asserted-by":"publisher","first-page":"3179","DOI":"10.1210\/clinem\/dgaa448","volume":"105","author":"MJ Kilberg","year":"2020","unstructured":"Kilberg MJ, Harris C, Sheikh S et al (2020) Hypoglycemia and islet dysfunction following oral glucose tolerance testing in pancreatic-insufficient cystic fibrosis. J Clin Endocrinol Metab 105(10):3179\u20133189. https:\/\/doi.org\/10.1210\/clinem\/dgaa448","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"6223_CR73","doi-asserted-by":"publisher","first-page":"e001289","DOI":"10.1136\/bmjresp-2022-001289","volume":"9","author":"R Jain","year":"2022","unstructured":"Jain R, Magaret A, Vu PT et al (2022) Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design. BMJ Open Respir Res 9(1):e001289. https:\/\/doi.org\/10.1136\/bmjresp-2022-001289","journal-title":"BMJ Open Respir Res"},{"key":"6223_CR74","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3389\/fendo.2018.00020","volume":"9","author":"K Kayani","year":"2018","unstructured":"Kayani K, Mohammed R, Mohiaddin H (2018) Cystic fibrosis-related diabetes. Front Endocrinol 9:20. https:\/\/doi.org\/10.3389\/fendo.2018.00020","journal-title":"Front Endocrinol"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-024-06223-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-024-06223-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-024-06223-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T18:10:39Z","timestamp":1764267039000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-024-06223-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,12]]},"references-count":74,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,10]]}},"alternative-id":["6223"],"URL":"https:\/\/doi.org\/10.1007\/s00125-024-06223-3","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,12]]},"assertion":[{"value":"27 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 May 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 August 2024","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Fig. 1 and Fig. 2 legends have the downloadable slideset's hyperlinks updated.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This review was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (R01DK119699) and the Cystic Fibrosis Foundation (Harry Shwachman Clinical Investigator Award and EnVision CF: Emerging Leaders in CF Endocrinology III Program).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"KJS declares that there are no relationships or activities that might bias, or be perceived to bias, their work. MSP has received in-kind support and research grants from Dexcom Inc., research grants and honoraria from Vertex Pharmaceuticals, and serves as a consultant for Anagram Therapeutics. BEM has received investigator-initiated research support from Tandem Diabetes Care, Inc. (TDC20210226), industry-sponsored research support from Medtronic, and research supplies from Dexcom, Inc. and Digostics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 relationships and activities"}},{"value":"All authors were involved in drafting the article and reviewing it critically for important intellectual content. All authors approved the final version to be published.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Contribution statement"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}]}}